South Dakota Investment Council increased its stake in shares of Allergan PLC. (NYSE:AGN) by 3.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 208,469 shares of the company’s stock after buying an additional 6,350 shares during the quarter. Allergan PLC. comprises approximately 0.9% of South Dakota Investment Council’s holdings, making the stock its 28th largest position. South Dakota Investment Council owned 0.06% of Allergan PLC. worth $42,726,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Howard Hughes Medical Institute bought a new position in shares of Allergan PLC. in the second quarter worth $103,000. Cable Hill Partners LLC grew its stake in shares of Allergan PLC. by 255.2% in the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. grew its stake in shares of Allergan PLC. by 283.7% in the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Jacobi Capital Management LLC grew its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after purchasing an additional 22 shares in the last quarter. Finally, Massey Quick & Co. LLC grew its stake in shares of Allergan PLC. by 334.8% in the second quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after purchasing an additional 385 shares in the last quarter. Hedge funds and other institutional investors own 81.65% of the company’s stock.

Shares of Allergan PLC. (AGN) opened at $174.83 on Friday. The stock has a market capitalization of $58,145.50, a PE ratio of 11.34, a P/E/G ratio of 1.11 and a beta of 1.13. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08. Allergan PLC. has a one year low of $169.61 and a one year high of $256.80.

Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.06 by $0.09. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business earned $3.32 EPS. analysts predict that Allergan PLC. will post 16.28 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, November 17th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.60%. The ex-dividend date is Thursday, November 16th. Allergan PLC.’s dividend payout ratio is currently -12.44%.

Allergan PLC. announced that its Board of Directors has initiated a stock repurchase program on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to purchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its shares are undervalued.

TRADEMARK VIOLATION WARNING: “South Dakota Investment Council Boosts Position in Allergan PLC. (AGN)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/11/24/south-dakota-investment-council-boosts-position-in-allergan-plc-agn.html.

AGN has been the subject of several research reports. Mizuho reaffirmed a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 2nd. Credit Suisse Group set a $288.00 target price on Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, August 5th. Royal Bank Of Canada set a $285.00 target price on Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, August 3rd. Deutsche Bank AG reaffirmed a “buy” rating and set a $278.00 target price (up previously from $273.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. Finally, Argus reaffirmed a “buy” rating and set a $280.00 target price on shares of Allergan PLC. in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $246.73.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.